Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pumitamig + Chemotherapy vs Atezolizumab + Chemotherapy in First-line ES-SCLC
NCT06712355Phase 3Recruiting
- Sponsor
- BioNTech SE
- Start
- Feb 2025
- Primary completion
- Apr 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of pumitamig in small cell lung cancer (SCLC), sponsored by BioNTech SE. Started Feb 2025; status: recruiting.
02
Drugs
pumitamig
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06712355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06712355.